50.90
price up icon1.52%   0.76
 
loading
Sanofi Adr stock is traded at $50.90, with a volume of 3.73M. It is up +1.52% in the last 24 hours and up +2.02% over the past month. Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
See More
Previous Close:
$50.14
Open:
$50.37
24h Volume:
3.73M
Relative Volume:
1.27
Market Cap:
$124.96B
Revenue:
$43.23B
Net Income/Loss:
$6.79B
P/E Ratio:
12.71
EPS:
4.0051
Net Cash Flow:
$9.17B
1W Performance:
+11.77%
1M Performance:
+2.02%
6M Performance:
-6.81%
1Y Performance:
-8.35%
1-Day Range:
Value
$50.33
$51.05
1-Week Range:
Value
$44.62
$51.05
52-Week Range:
Value
$44.62
$60.12

Sanofi Adr Stock (SNY) Company Profile

Name
Name
Sanofi Adr
Name
Phone
-
Name
Address
-
Name
Employee
82,878
Name
Twitter
@sanofi
Name
Next Earnings Date
2024-10-25
Name
Latest SEC Filings
Name
SNY's Discussions on Twitter

Compare SNY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
SNY
Sanofi Adr
50.90 122.19B 43.23B 6.79B 9.17B 4.0051
Drug Manufacturers - General icon
LLY
Lilly Eli Co
839.87 734.96B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
188.64 447.90B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
233.91 417.90B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
132.39 253.54B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
89.19 223.58B 63.43B 16.42B 14.72B 6.4861

Sanofi Adr Stock (SNY) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-08-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-02-25 Upgrade Deutsche Bank Hold → Buy
Aug-08-25 Upgrade JP Morgan Neutral → Overweight
Apr-15-25 Initiated Exane BNP Paribas Outperform
Mar-21-25 Initiated Goldman Neutral
Jan-30-25 Upgrade Deutsche Bank Sell → Hold
Jul-26-24 Reiterated Argus Buy
Jan-23-24 Initiated Morgan Stanley Equal-Weight
Jan-16-24 Resumed UBS Buy
Dec-05-23 Downgrade JP Morgan Overweight → Neutral
Oct-30-23 Downgrade Stifel Buy → Hold
Sep-06-23 Upgrade Berenberg Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Apr-28-23 Downgrade Deutsche Bank Hold → Sell
Mar-27-23 Upgrade Barclays Equal Weight → Overweight
Dec-13-22 Resumed Morgan Stanley Overweight
Aug-12-22 Upgrade Deutsche Bank Sell → Hold
Aug-09-22 Downgrade UBS Buy → Neutral
May-23-22 Initiated SVB Leerink Outperform
Sep-27-21 Upgrade SVB Leerink Mkt Perform → Outperform
Jan-15-21 Initiated Deutsche Bank Sell
Sep-29-20 Initiated Berenberg Hold
Mar-17-20 Upgrade Barclays Underweight → Equal Weight
Mar-11-20 Upgrade Goldman Neutral → Buy
Feb-11-20 Initiated SVB Leerink Mkt Perform
Jan-06-20 Upgrade JP Morgan Neutral → Overweight
Sep-23-19 Upgrade Guggenheim Neutral → Buy
Sep-20-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-03-19 Initiated Bernstein Outperform
Aug-14-19 Upgrade UBS Neutral → Buy
Dec-11-18 Upgrade Jefferies Hold → Buy
Nov-01-18 Upgrade Barclays Underweight → Equal Weight
Oct-09-18 Initiated Guggenheim Neutral
Sep-10-18 Upgrade BofA/Merrill Neutral → Buy
Aug-10-18 Upgrade Citigroup Neutral → Buy
Mar-23-18 Upgrade Liberum Hold → Buy
Jan-23-18 Downgrade Barclays Equal Weight → Underweight
Dec-06-17 Downgrade BofA/Merrill Buy → Neutral
Dec-01-17 Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17 Upgrade Barclays Underweight → Equal Weight
Aug-30-17 Upgrade HSBC Securities Reduce → Hold
View All

Sanofi Adr Stock (SNY) Latest News

pulisher
Oct 02, 2025

Leerink Partners Sticks to Its Buy Rating for Sanofi (SNYNF) - The Globe and Mail

Oct 02, 2025
pulisher
Sep 29, 2025

BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals

Sep 29, 2025
pulisher
Sep 26, 2025

Sanofi Expands Insulin Savings Program To Cover All US Patients - Benzinga

Sep 26, 2025
pulisher
Sep 17, 2025

Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability - Sahm

Sep 17, 2025
pulisher
Sep 16, 2025

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit - Sahm

Sep 16, 2025
pulisher
Sep 12, 2025

Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.

Sep 12, 2025
pulisher
Sep 10, 2025

Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS® - Ariva

Sep 10, 2025
pulisher
Sep 04, 2025

What's Going On With Nektar Therapeutics Stock On Thursday? - Sahm

Sep 04, 2025
pulisher
Sep 04, 2025

Why Is Sanofi Stock Falling Thursday? - Sahm

Sep 04, 2025
pulisher
Sep 04, 2025

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors - Sahm

Sep 04, 2025
pulisher
Aug 26, 2025

New Report Highlights Community Health Workers' Impact, Calls for Sustained Local Investment, During National CHW Awareness Week - Ariva

Aug 26, 2025
pulisher
Aug 21, 2025

European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest

Aug 21, 2025
pulisher
Aug 05, 2025

Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar

Aug 05, 2025
pulisher
Aug 05, 2025

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2025 Commentary - Seeking Alpha

Aug 05, 2025
pulisher
Jul 31, 2025

Sanofi ADR (SNY) Stock: A Year of Stock Market Ups and Downs - investchronicle.com

Jul 31, 2025
pulisher
Jul 31, 2025

Sanofi ADR earnings beat by $0.63, revenue fell short of estimates - Investing.com Nigeria

Jul 31, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com

Jul 27, 2025
pulisher
Jul 24, 2025

Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar

Jul 24, 2025
pulisher
Jul 22, 2025

BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva

Jul 22, 2025
pulisher
Jul 21, 2025

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com

Jul 21, 2025
pulisher
Jul 14, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SanofiSNY - FinancialContent

Jul 14, 2025

Sanofi Adr Stock (SNY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$112.69
price up icon 1.93%
drug_manufacturers_general PFE
$27.37
price up icon 1.07%
$297.89
price up icon 0.16%
drug_manufacturers_general NVO
$59.63
price up icon 1.52%
drug_manufacturers_general MRK
$89.19
price down icon 0.36%
Cap:     |  Volume (24h):